Opus Genetics, Inc.

IRD · Nasdaq · United States

Share price · IRD

$3.92+0.23 (+6.23%) 3M

close as of 2026-11-18 · 24h delayed · vol 752K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when IRD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Sep 2026+32.0%
  2. 2 Sep 2026+16.2%
  3. 30 Jul 2026+10.7%

    Nothing announced by IRD that day or the session before.

  4. 27 Jul 2026+8.8%

    Nothing announced by IRD that day or the session before.

  5. 24 Jun 2026-9.1%

    Nothing announced by IRD that day or the session before.

  6. 5 Jun 2026-13.1%

    Nothing announced by IRD that day or the session before.

  7. 4 Jun 2026+10.5%

    Nothing announced by IRD that day or the session before.

  8. 27 Feb 2026+15.9%

    Nothing announced by IRD that day or the session before.

  9. 9 Feb 2026+12.3%

    Nothing announced by IRD that day or the session before.

  10. 6 Feb 2026+16.7%

    Nothing announced by IRD that day or the session before.

Share of unusual movement by asset

For each asset, the share of IRD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
OPGx-LCA5
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—23%
Sessions with no dated event—76%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
LCA5 (lebercilin) gene replacementGene therapy / editing
Leber Congenital Amaurosis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
OPGx-LCA5Phase 1/2LCA5
Est. primary completion 2028-06-15 · NCT05616793 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2025Topline resultOPGx-LCA5Positive pediatric and adult data from OPGx-LCA5 Phase 1/2 trial

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.1M$14M$89M$47M-$14M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.8M$11M$89M$8.1M-$12M operating cash flowreport ↗
2026-Q1$2.2M$11M$60M$66M-$13M operating cash flowreport ↗
2025-Q3$3.1M$6.4M$31M+ $0 short-term inv.$17M-$6.2M operating cash flowreport ↗
2025-Q2$2.9M$6.0M$32M+ $0 short-term inv.$7.4M-$10M operating cash flowreport ↗
2025-Q1$4.4M$8.0M$42M+ $0 short-term inv.$8.2M-$9.0M operating cash flowreport ↗
2024-Q3$3.9M$9.0M$37M+ $0 short-term inv.$7.5M-$5.1M operating cash flowreport ↗
2024-Q2$1.1M$6.1M$41M+ <$0.1M short-term inv.$7.8M-$7.3M operating cash flowreport ↗
2024-Q1$1.7M$4.8M$47M+ <$0.1M short-term inv.$7.1M-$5.7M operating cash flowreport ↗
2023-Q3$12M$3.5M$42M+ <$0.1M short-term inv.—-$3.0M operating cash flowreport ↗
2023-Q2$3.7M$4.7M$40M+ <$0.1M short-term inv.$5.0M$1.0M operating cash flowreport ↗
2023-Q1$1.8M$5.6M$39M+ <$0.1M short-term inv.$5.8M-$3.6M operating cash flowreport ↗
2022-Q3$0$2.8M$14M+ $0.1M short-term inv.$4.5M-$4.5M operating cash flowreport ↗
2022-Q2$0$3.2M$17M+ $0.1M short-term inv.$4.9M-$3.8M operating cash flowreport ↗
2022-Q1$0$4.8M$19M+ $0.1M short-term inv.$6.6M-$6.2M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$14M$31M$45M+ $0 short-term inv.$12M-$35M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$11M$27M$30M+ $0 short-term inv.$14M-$26M operating cash flowreport ↗
2023-FY$19M$18M$51M+ <$0.1M short-term inv.$2.5M-$1.1M operating cash flowreport ↗
2022-FY$40M$14M$43M+ $0.1M short-term inv.—$14M operating cash flowreport ↗
2021-FY$0.6M$15M$25M+ $0.2M short-term inv.$14M-$19M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($324K), 24 sales ($19.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Magrath George · director, Chief Executive OfficerOpen-market sale28,258$3.90$110KForm 4
2026-10-23Magrath George · director, Chief Executive OfficerOpen-market sale9,591$3.58$34KForm 4
2026-10-23Gagnon Robert E. · Chief Financial OfficerOpen-market sale14,000$3.55$50KForm 4
2026-10-23YERXA BENJAMIN R · director, PresidentOpen-market sale7,669$3.55$27KForm 4
2026-10-23SCHACHLE JOSEPH K · Chief Operating OfficerOpen-market sale4,767$3.56$17KForm 4
2026-10-23YERXA BENJAMIN R · director, PresidentOpen-market sale25,520$3.53$90KForm 4
2026-09-30Foundation Fighting Blindness Retinal Degeneration Fund; Foundation Fighting Blindness, Inc. · director; directorOpen-market sale556,000$4.96$2.8MForm 4
2026-09-09Magrath George · director, Chief Executive OfficerOption exercise392,157$1.15$451KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 79 reporting institutions held 45.4M shares ($203.4M, 47.0% of shares outstanding).

#InstitutionSharesValue
1Caligan Partners LP6,075,028$27.6M
2ADAGE CAPITAL PARTNERS GP, L.L.C.6,029,775$27.4M
3BIOS Capital Management, LP3,683,429$16.8M
4Balyasny Asset Management L.P.2,718,029$12.4M
5MILLENNIUM MANAGEMENT LLC2,630,432$12.0M
6VANGUARD CAPITAL MANAGEMENT LLC2,449,987$11.1M
7MARSHALL WACE, LLP2,313,380$10.5M
8Boxer Capital Management, LLC2,250,000$10.2M
9ADAR1 Capital Management, LLC1,849,004$8.4M
10PERCEPTIVE ADVISORS LLC1,835,842$8.4M
11Nantahala Capital Management, LLC1,681,330$7.7M
12Woodline Partners LP1,354,030$6.2M
13BOOTHBAY FUND MANAGEMENT, LLC1,189,113$5.4M
14FARALLON CAPITAL MANAGEMENT LLC1,000,000$4.5M
15SUSQUEHANNA INTERNATIONAL GROUP, LLP823,383$3.7M